Publications by authors named "Lucas Mose"
Article Synopsis
- * A study analyzed 156 patients, finding that the majority were male (62%), with a median age of 64 years. The most common types of cancer were squamous cell carcinoma, adenocarcinoma, and malignant melanoma.
- * The results showed generally low morbidity post-surgery, but patients undergoing radiation therapy experienced more acute side effects like dermatitis and mucositis. Several factors, including cancer type and skull base involvement, negatively impacted overall and recurrence-free survival rates.
Article Synopsis
- Salvage radiation therapy (sRT) is crucial for patients who experience biochemical recurrence after prostate surgery, and a new nomogram has been developed to predict their chances of remaining free from this recurrence.
- * This study aims to evaluate the effectiveness of PSMA-PET-based assessments in guiding sRT for cases of prostate-specific antigen (PSA) persistence or recurrence, and it seeks to improve predictive models using random survival forests compared to traditional Cox models.
- * Data from 1029 patients across five countries were analyzed to validate these predictive models, utilizing machine learning techniques to better understand outcomes related to biochemical failure after treatment.
Brainstem metastases (BSM) present a significant neuro-oncological challenge, resulting in profound neurological deficits and poor survival outcomes. Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) offer promising therapeutic avenues for BSM despite their precarious location. This international multicenter study investigates the efficacy and safety of SRS and FSRT in 136 patients with 144 BSM treated at nine institutions from 2005 to 2022.
View Article and Find Full Text PDFIntroduction: Enzalutamide, a second-generation androgen receptor inhibitor, is indicated for the treatment of metastatic disease, as well as in the treatment of non-metastatic castration resistant prostate cancer (PCa). This systematic review aims to determine outcomes and toxicity in patients with non-metastatic castration sensitive prostate cancer (nmCSPC) treated with enzalutamide in the primary or salvage settings.
Method: We performed a systematic review focusing on the role of Enzalutamide in the treatment of nmCSPC, using the PubMed/Medline database.
Purpose: To compare two stereotactic body radiotherapy (SBRT) regimens in patients with intermediate- or high-risk prostate cancer with regards toxicity and efficacy.
Methods/material: We retrospectively collected data from 198 patients treated with SBRT for prostate cancer at two different institutions. Patients received either 35-36.
Article Synopsis
- * A study analyzed 41 patients undergoing SRS while on ACT, monitoring for ICH occurrences over an average follow-up of 8.2 months, finding a low risk of bleeding with no significant neurological deficits or deaths linked to ICH.
- * The results showed cumulative ICH incidences of 2.1%, 12.4%, and 12.4%
Background: Due to recent medical advancements, patients suffering from metastatic spinal disease have a prolonged life expectancy than several decades ago, and some will eventually experience relapses. Data for the retreatment of spinal metastasis recurrences occurring at the very same macroscopic spot as the initially treated lesion are limited. Previous studies mainly included recurrences in the boundary areas as well as other macroscopic parts of the initially affected vertebrae.
View Article and Find Full Text PDF